Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Conditions
Interventions
BGJ398
BYL719
Locations
22
United States
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
Tampa, Florida, United States
University of Michigan Comprehensive Cancer Center SC
Ann Arbor, Michigan, United States
Karmanos Cancer Institute Dept of Onc
Detroit, Michigan, United States
Washington University School of Medicine Onc Dept
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center Onc Dept
New York, New York, United States
Vanderbilt University Medical Center Dept of Onc
Nashville, Tennessee, United States
Start Date
October 1, 2013
Primary Completion Date
August 1, 2016
Completion Date
August 1, 2016
Last Updated
December 9, 2020
NCT06898450
NCT05719558
NCT06307795
NCT06716138
NCT07029399
NCT04826341
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions